Advertisement
Screener

VolitionRx Limited (VNRX) Overview

VolitionRx Limited (VNRX) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.85; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.97; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -0.05; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -1.22; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$0.23$0.52$1.19$2.73$6.24$14.282025-09-292026-09-29$0.23$0.75$2.45$8.06$26.43$86.732021-09-292026-09-29$0.23$0.82$2.94$10.57$37.99$136.502016-09-292026-09-29$0.23$0.82$2.94$10.57$37.99$136.502012-03-022026-09-29$0.23$0.82$2.94$10.57$37.99$136.502012-03-022026-09-29

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$0.26
Previous close
$0.25
Change
$0.01
Change (%)
4.00%
Close date
2026-09-29
Previous close date
2026-09-28
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

VNRX
-95.00%
S&P 500
(m)

1 year

VNRX
-97.90%
S&P 500
(m)

3 years

VNRX
-98.12%
S&P 500
(m)

5 years

VNRX
-99.58%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual -0.85

-1.30-0.94-0.58-0.230.1331 Mar 2025: estimate (m); actual -1.1231 Mar 2025(m)30 Jun 2025: estimate (m); actual -1.2230 Jun 2025(m)30 Sept 2025: estimate (m); actual -0.0530 Sept 2025(m)31 Mar 2026: estimate (m); actual -0.9731 Mar 2026(m)30 Jun 2026: estimate (m); actual -0.8530 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)-0.85(m)(m)
1 Jan 202631 Mar 2026(m)-0.97(m)(m)
1 Jul 202530 Sept 2025(m)-0.05(m)(m)
1 Apr 202530 Jun 2025(m)-1.22(m)(m)
1 Jan 202531 Mar 2025(m)-1.12(m)(m)

31 Dec 2024 ○ Estimate (m) ● Actual -0.31

-0.58-0.47-0.35-0.24-0.1331 Dec 2023: estimate (m); actual -0.5031 Dec 2023(m)31 Dec 2024: estimate (m); actual -0.3131 Dec 2024(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202431 Dec 2024(m)-0.31(m)(m)
1 Jan 202331 Dec 2023(m)-0.50(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 0.40M ■ Earnings -7.33M — Profit margin -1837.68%

-8.32M-1838.7%-4.89M-1451.0%-1.45M-1063.3%1.98M-675.6%30 Sept 2025: revenue 0.63M; earnings -5.38M; profit margin -857.41%30 Sept 202531 Dec 2025: revenue 0.45M*; earnings -6.27M*; profit margin -1402.76%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 0.99M; earnings -6.66M; profit margin -676.57%31 Mar 202630 Jun 2026: revenue 0.40M; earnings -7.33M; profit margin -1837.68%30 Jun 2026

31 Dec 2025 ■ Revenue 1.73M ■ Earnings -23.36M — Profit margin -1352.16%

-40.17M-9987.7%-24.71M-7108.9%-9.24M-4230.0%6.22M-1351.2%31 Dec 2022: revenue 0.31M; earnings -30.60M; profit margin -9986.71%31 Dec 202231 Dec 2023: revenue 0.78M; earnings -35.68M; profit margin -4601.70%31 Dec 202331 Dec 2024: revenue 1.23M; earnings -26.97M; profit margin -2186.27%31 Dec 202431 Dec 2025: revenue 1.73M; earnings -23.36M; profit margin -1352.16%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$0.26(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$0.26High(m)Average(m)Low(m)2025-09-292026-09-29

Recent news

View more →

(m)

YouTube videos mentioning VNRX

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending (m).

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
(m)
Profit margin
(m)
Return on assets · 12 month
(m)
Stock compensation expense · all employees · 12 months
(m)
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
(m)
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
3.23M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
0.00%*
Total return · month
-40.91%*
Total return · quarter
-81.69%*
Total return · half year
-93.50%*
Total return · year to date
-95.00%*
Total return · 1 year
-97.90%*
Total return · 3 years
-98.12%*
Total return · 5 years
-99.58%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
(m)
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

VolitionRx Limited Overview

View more →

(m)

(m)

SEC CIK
93314
Industry (SIC)
2835 In Vitro & In Vivo Diagnostic Substances
Country of operation
United States
Business address
1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON, Nevada, 89014, United States
Fiscal year end
1231
Phone
1 (512) 774-8930

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cardio Diagnostics Holdings, Inc. (CDIO)United States$0.006B
Q/C TECHNOLOGIES, INC. (QCLS)United States$0.008B-1.93
BIOMERICA INC (BMRA)United States$0.011B
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92